TD Asset Management
CBIO

TD Asset Management’s Crescent Biopharma CBIO Stock Holding History

TD Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-642
Closed -$765K – 1348
2019
Q2 		$765K Sell
642
-101
-14% -$121K ﹤0.01% 1102
2019
Q1 		$926K Sell
743
-18
-2% -$20.6K ﹤0.01% 1056
2018
Q4 		$721K Buy
761
+34
+5% +$40.9K ﹤0.01% 1138
2018
Q3 		$1.05M Buy
727
+35
+5% +$52.9K ﹤0.01% 1153
2018
Q2 		$1.12M Buy
692
+127
+22% +$218K ﹤0.01% 1106
2018
Q1 		$917K Buy
565
+315
+126% +$655K ﹤0.01% 1082
2017
Q4 		$420K Sell
250
-3
-1% -$3.97K ﹤0.01% 1218
2017
Q3 		$354K Sell
253
-71
-22% -$83.4K ﹤0.01% 1213
2017
Q2 		$362K Buy
+324
New +$268K ﹤0.01% 1238

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

TD Asset Management's CBIO Position: Q3 2019 in Review

TD Asset Management sold out of Crescent Biopharma (CBIO) in Q3 2019, closing a stake of 642 shares — an estimated $765K sold.

TD Asset Management first reported a position in CBIO in Q2 2017 and held it in 9 quarters. The position peaked at $1.12M in Q2 2018. 75 funds tracked by Wall St. Rank hold CBIO as of Q3 2019.

  • TD Asset Management reported no remaining Crescent Biopharma position as of Q3 2019 after selling out during the quarter.
  • TD Asset Management sold 642 Crescent Biopharma shares in Q3 2019, an estimated $765K.
  • TD Asset Management first reported a position in Crescent Biopharma in Q2 2017 and held it in 9 quarters.
  • TD Asset Management's Crescent Biopharma position peaked at $1.12M in Q2 2018.
  • 75 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2019.

Based on TD Asset Management's 13F filing for Q3 2019, filed 7 Nov 2019.